Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1001 to 1050 of 1958 results for news

  1. Cystic fibrosis (QS168)

    This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.

  2. Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)

    Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

  3. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

  4. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

  5. Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.

  6. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.

  7. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  8. Executive team

    Day-to-day decision making is the responsibility of NICE's executive team.

  9. Using our recommendations: maternity and neonatal health

    How to use NICE guidance to reduce health inequalities during and after pregnancy.

  10. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

  11. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  12. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

  13. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

    Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.

  14. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.

  15. AlignRT for intracranial stereotactic radiosurgery (MIB147)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .

  16. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  17. Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)

    This quality standard covers recognition, early intervention and long-term management of bipolar disorder, psychosis and schizophrenia in children and young people (under 18). It also includes support for parents and carers. It describes high-quality care in priority areas for improvement.

  18. Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) (QS210)

    This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.

  19. Autism (QS51)

    This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.

  20. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.

  21. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

  22. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

  23. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  24. Coexisting severe mental illness and substance misuse: community health and social care services (NG58)

    This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.

  25. Faltering growth: recognition and management of faltering growth in children (NG75)

    This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.

  26. Cataracts in adults: management (NG77)

    This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.

  27. Constipation in children and young people: diagnosis and management (CG99)

    This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.

  28. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

    Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.

  29. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

  30. Self-sampling and self-testing:- How effective are self-sampling and self-testing in terms of accuracy of sampling, ability to reach different groups, test completion, receipt of results and subsequent care-seeking behaviour?

    Why this is important:- Self-sampling and self-testing are relatively new modalities in the UK and limited evidence exists about their...

  31. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  32. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

  33. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, is collected for all people treated with sofosbuvir in the NHS.

    England is intending to collect clinical data from people treated with the new generation of HCV treatments. NICE agreed that such...

  34. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

  35. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

  36. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

  37. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  38. What is the long-term effect of laparoscopic cholecystectomy on outcomes that are important to patients?

    outcomes. Many patients report a continuation of symptoms or the onset of new symptoms after laparoscopic cholecystectomy, and these...

  39. Integrated health and social care for people experiencing homelessness (NG214)

    This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

  40. The evidence on cardiac contractility modulation device implantation for heart failure raises no major safety concerns. However, the evidence on efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of  research .

    stimulation. Outcomes should include ejection fraction, oxygen consumption, New York Heart Association classification and...

  41. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    intending to collect clinical data from people having treatment with the new generation of hepatitis C virus treatments. NICE agreed...

  42. eXroid for internal haemorrhoids (MIB201)

    NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .

  43. PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection (MIB200)

    NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .

  44. Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)

    NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital

  45. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

  46. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

    Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

  47. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

  48. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

    Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.

  49. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.